<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996797</url>
  </required_header>
  <id_info>
    <org_study_id>PR200-102</org_study_id>
    <secondary_id>2021-000091-11</secondary_id>
    <nct_id>NCT04996797</nct_id>
  </id_info>
  <brief_title>A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <acronym>ARTEMIS-UC</acronym>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prometheus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prometheus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of PRA023 in participants with&#xD;
      moderately to severely active Ulcerative Colitis.&#xD;
&#xD;
      The purpose of Cohort 2 of the study is to assess the safety and efficacy of PRA023 in&#xD;
      participants with moderately to severely active ulcerative colitis who are companion&#xD;
      diagnostic positive.&#xD;
&#xD;
      After the completion of the 12-week induction, all participants have the option to continue&#xD;
      in the open-label extension for another 38 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction of clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of clinical remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Week 12</time_frame>
    <description>Incidence of AE, SAE, AE leading to discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction of endoscopic improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of endoscopic improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of clinical response</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of clinical remission in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of clinical remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of histologic remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of histologic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of histologic-endoscopic mucosal improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of histologic- endoscopic mucosal improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of endoscopic improvement in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of endoscopic improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of clinical response in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of histologic remission in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of histologic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of histologic-endoscopic mucosal improvement in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of histologic-endoscopic mucosal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission in CDx+ vs. CDx- participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of of CDx+ vs. CDx- participants achieving clinical remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of mucosal healing</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of mucosal healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of mucosal healing in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving induction of mucosal healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IBDQ</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from Baseline in IBDQ through Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IBDQ in CDx+ participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from Baseline in IBDQ through Week 12 in CDx+ participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of Clinical remission in CDx+ participants per alternative algorithm</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants per alternative algorithm achieving induction of Clinical remission</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 PRA023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive PRA023 administered by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant randomized to receive placebo administered by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDx+ Expansion Cohort PRA023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive PRA023 administered by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDx+ Expansion Cohort Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant randomized to receive placebo administered by intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRA023 IV</intervention_name>
    <description>PRA023 administered by IV infusion</description>
    <arm_group_label>CDx+ Expansion Cohort PRA023</arm_group_label>
    <arm_group_label>Cohort 1 PRA023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Companion Diagnostic (CDx) Testing</intervention_name>
    <description>PRA023 CDx Genotyping Assay</description>
    <arm_group_label>CDx+ Expansion Cohort PRA023</arm_group_label>
    <arm_group_label>CDx+ Expansion Cohort Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered by IV infusion</description>
    <arm_group_label>CDx+ Expansion Cohort Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of ulcerative colitis (UC)&#xD;
&#xD;
          -  Moderately to severely active UC as defined by 3-component Modified Mayo score&#xD;
&#xD;
          -  Must have corticosteroid dependence or have had no response, insufficient response,&#xD;
             loss of response, and/or intolerance to at least one of the following therapies:&#xD;
             corticosteroid, immunosuppressants, or an approved anti-TNF, anti-integrin,&#xD;
             anti-IL12/23, JAK inhibitor, S1PR modulator.&#xD;
&#xD;
          -  Able to provide written informed consent and understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP and men with female partners of childbearing potential who are unwilling or&#xD;
             unable to use two highly effective methods of contraception to avoid pregnancy for the&#xD;
             entire study period and for up to 12 weeks after the last dose of study drug&#xD;
&#xD;
          -  Diagnosis of Crohn's disease or indeterminate colitis&#xD;
&#xD;
          -  Current evidence of fulminant colitis, toxic megacolon, bowel perforation, total&#xD;
             proctocoloectomy or partial colectomy&#xD;
&#xD;
          -  Current or impending need for colostomy or ileostomy&#xD;
&#xD;
          -  Surgical bowel resection within 3 months before screening&#xD;
&#xD;
          -  Past or current evidence of definite low-grade or high-grade colonic dysplasia not&#xD;
             completely removed&#xD;
&#xD;
          -  Subjects in the opinion of the investigator are at an unacceptable risk for&#xD;
             participation in the study&#xD;
&#xD;
          -  Subjects who meet the protocol criteria for important laboratory exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prometheus Biosciences</last_name>
    <role>Study Director</role>
    <affiliation>Clinicaltrials Call center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prometheus Biosciences</last_name>
    <phone>+1-858-332-0362</phone>
    <email>Clinicaltrials@prometheusbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARTEMIS-UC</keyword>
  <keyword>ARTEMIS</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

